In summary, there is a large body of evidence that increased NRF2 levels are associated with (a) various tumour-promoting functions in malignant gliomas, (b) negative patient survival in diffuse gliomas and glioblastomas, (c) tumour cell senescence [254], and (d) resistance towards radio-chemotherapy. Here, NFE2L2 is linked to malignant glioma.